The Pistoia Union encourages large pharmaceutical companies to work together to carry out block chain plans

nnnThe Pistoia Alliance is a nonprofit organization in the life sciences industry that aims to reduce barriers to research and development in this area. Including GlaxoSmithKline, Roche, Pfizer and other major pharmaceutical companies in the world, are its members. The league recently released a seminar survey, showing that the pharmaceutical industry has great enthusiasm for the block chain, to encourage pharmaceutical companies to start the relevant cooperation, and ultimately enable researchers and patients can profit.n
nnTranslated by: Inan
nThe Pistoia Union recently published its findings for its Advanced Pharmaceutical and Life Sciences webinar workshop.n
nn22% of the life sciences companies have implemented or tested the block chain technologyn
n83% of respondents expect to use block chains in the next five yearsn
nnThe Pistoia Alliance is a nonprofit organization that brings together life sciences companies, suppliers, publishers and academic groups whose mission is to reduce the barriers to innovation in life science research and development.n
nOn June 26 (Monday), the Pistoia Union released a survey showing the enthusiasm of the pharmaceutical industry for block chains. The majority of respondents (83%) are expected to use block chains over the next five years.n
nThus, the Pistoia Union is promoting cooperation among stakeholders, especially in the early stages of adoption. The alliance recommends that industry-wide data sharing standards improve safety and motivate patients to share their data with the company. These advances will benefit researchers and patients in the present and in the future.n
nForty-five percent of respondents believe that regulatory issues are the biggest barrier to widespread use of block-chain technology. Potential concerns about data privacy (26% of respondents hold this view) are the second major hurdle.n
nIn the use case, 68% of respondents believe that block chains can have the greatest impact by “ensuring a censable path to protect drug sources” or tracking drugs. 60% of respondents also noted the use of block-chain technology to store medical records.n
nIn the e-mail to ETHNews, Pesta Union adviser Nick Lynch explained that the block chain has been able to draw the interest of the pharmaceutical industry because “it can provide a secure, scalable, non-mediated system for data storage.” “n
nLynch also said that because the block chain allows patients to control their own data and its use, so it can transfer the right from the doctor to the patient. “In the future, patients can even profit from their personal data access, allowing individual companies to access their data blocks for research.”n
nn”This will change the overall health model from early research and development to final delivery, and the pharmaceutical industry must work together to explore solutions that enable patients to control their personal data while ensuring that they can access data for their R u0026 D projects.”n

Leave a Reply

Your email address will not be published. Required fields are marked *